Instrumento Inactivo

Otros idiomas Bavarian Nordic A/S CBOE EUROPE EQUITIES

Acciones

DK0015998017

Precio de cierre CBOE EUROPE EQUITIES Otros sitios de cotización
- ^DKK	-

08/05	Transcript : Bavarian Nordic A/S, Q1 2024 Earnings Call, May 08, 2024
08/05	Bavarian Nordic A/S ofrece una previsión de beneficios para el año 2024	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations	08/05
Bavarian Nordic A/S : Interim Results (Q1) as of 31 March 2024	08/05
Bavarian Nordic Announces Interim Results for the First Three Months of 2024	08/05
Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024	08/05
Bavarian Nordic A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such	07/05
Bavarian Nordic Books EUR65 Million Order for Smallpox Vaccine	30/04
Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve	29/04
Bavarian Nordic A/S Receives EUR 65 Million Contract to Supply Smallpox Vaccines for EU Strategic Reserve	29/04
Bavarian Nordic Starts US Rolling Submission Process for Chikungunya Vaccine Candidate	29/04
Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate	29/04
Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate	29/04
ExpreS2ion to receive approximately SEK 22.5 million dividend payment from AdaptVac ApS	23/04
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such	22/04
Resolutions of the Annual General Meeting 2024 of Bavarian Nordic A/S	16/04
Morris & Dickson is the First U.S. Distributor for Bavarian Nordic's JYNNEOS, the Only FDA-approved Mpox Vaccine	04/04
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.	02/04
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.	02/04
Bavarian Nordic A/S : Notice Convening Annual General Meeting	21/03
Bavarian Nordic A/S – Notice Convening Annual General Meeting	21/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Bavarian Nordic A/S CBOE EUROPE EQUITIES

Acciones

DK0015998017

Otros idiomas

Filtros